Failure - the Podcast

Failure - the Podcast
Failure - the Podcast

A podcast about innovation and failure, mostly in business. Visit us at https://innovationblab.com.

  1. 8 ENE

    NonProfitPalooza

    Today’s episode, NonProfitPalooza, might better be titled “How I Learned to Stop Worrying and Love Overachievers.” Our guests are Marissa Fayer and Brody Galloway, both of whom founded and actively run MedTech nonprofits. Were that not enough, they also hold day jobs. Marissa Fayer is the founder and CEO of HERhealthEQ, an organization dedicated to reducing the equity gap in access to healthcare for women around the world — or, more simply put, deploying medical equipment to maternal health patients that really need it. When we spoke with her, she was just back from Ghana, where HERhealthEQ was installing screening and cervical cancer testing gear. All told, the organization has 10 clinics serving over 3.2 million patients, worldwide. Let’s not forget that Marissa is also the CEO of DeepLook Medical, a for-profit that is commercializing technology that empowers health care providers to detect and diagnose lesions with unprecedented accuracy. Brody Galloway is just starting his career, but what a start it is. In addition to holding an A+ average in high school, Brody is the founder and CEO of Envision MedTech, a nonprofit dedicated to providing access to pediatric medical technology. To date, it has saved 13 lives, distributed 5,000 pediatric medical devices to underserved communities, and raised $7,000,000 in donations. Did we mention that Brody is still in high school? [Editor’s note: our copywriter is suffering from post-election puffery and got a bit carried away. We really have no clue as to Brody’s grade point average, though, it’s possible it might be A+, so let’s go with that. Oh, and the $7M raise, that may be off by three orders of magnitude. Again, our apologies. We hope our copywriter will cool his jets, now that we’ve settled into an era of unilateral re-dos of the Panama Canal sale and forceful takeovers of Greenland.] What might you, our one listener [Editor’s note: don’t worry, Rachel, we won’t name names] learn from our session with Marissa and Brody? First, that snark is so 2010’s and just isn’t funny anymore — though, we anxiously await an even more sinister return of this mocking form of expression, now that Donald Trump, Jr., is back in the spotlight. Second, that snark never did and never will work with interview subjects that are doing actual good. Finally, that market gaps are as important to nonprofit startups as they are to for-profits. On that latter note, today’s guests capitalized (no pun intended) on gaps in health care delivery to ensure success, not only in treating the underserved, but also in getting in-kind and cash sponsors. OK, ok, ok. But will you, dear listener, actually learn something from today’s episode? Doubtful. We’ve been monitoring the stats, and we know that all you do is loop the outro music at the end of each podcast. We get it: it’s catchy. There’s no need to be embarrassed. That’s all Jeff listens to, even if you count the 60+ minutes he’s in the recording session. (By the way, Jeff, are you ever going to repost us to your 57,243 LinkedIn followers? [Editor's note: just testing to see if Jeff even reads these blurbs.]) Enough said. Enjoy the show!

    49 min
  2. Ethics in Licensing Artificial Intelligence - Consumer Apps

    3 ENE

    Ethics in Licensing Artificial Intelligence - Consumer Apps

    Artificial intelligence (AI) is new to most of us, though it has been in development since the 1950s and the key to self-driving cars on the roads in the 1980s and popularized in the 2010s. Still, most of us only became aware of AI’s power with the release of ChatGPT, in late 2022. That’s when AI’s benefits and risks became a regular topic at the water cooler, apart from occasional discussion of a crashed Tesla. Governments took note of AI somewhat earlier, with self-driving car legislation emerging from the states in the 2010s and from the federal government late in that period. Legislation has been slower in the making when it comes to AI writ large, with the first laws not emerging until nearly the 2020s. Whether for autonomous vehicles or the broader category of AI-based consumer products that are beginning to hit the markets, government regulation may be too little and too late. Can the private sector do better — and, if so, could technology and data licensing agreements provide a viable mechanism for regulating AI in consumer products? Join a panel discussion on the ethics of AI and how it might inform drafting those agreements as this new technology takes hold in the marketplace. The particular focus is on the fairness of those agreements, when the value of consumer data collected by AI apps is taken into account — as it rarely is. Our guests are Nicholas Mattei, Associate Professor of Computer Science at Tulane University School of Science & Engineering; Rob Lalka, Professor of Practice in Management and the Albert R. Lepage Professor in Business, Tulane University, A. B. Freeman School of Business and the Executive Director of the Albert Lepage Center for Entrepreneurship and Innovation; and, Eric Gottschling, Global Director - Licensing Commercialization, Borg Warner. This episode's discussion was a run-up to a live talk at the annual meeting of the Licensing Executive Society (USA/Canada) in October 2024.

    52 min
  3. 15/09/2024

    Public Health Reflux ... er ... Redux

    Long time listener, first time caller? We got one of those, the other day. David’s brother, Dr. Seth Powsner, requested a live session with the team from Failure—the Podcast/Innovation Blab to take us to task.  We convened on a Saturday to accommodate.    The good doctor, a professor at Yale and a practicing ER physician, would seem to have the credentials to take us on. He wouldn’t admit to being a long-time listener of this podcast, but he let on that he’d mistakenly heard our last episode, “Drugged Out.” (He claims he stumbled over it on a NY Times Wirecutter list of top sleep podcasts). Turns out that our view of the public health system is all wrong:  only a limited number of diseases can be cured.  We’d thought we’d learned otherwise from a prior guest, who said that the cures were there — including, perhaps, for diabetes — but that financial incentives were keeping them from the market. The good doctor felt otherwise. Yes, the health care payment system isn’t optimal, but that isn’t necessarily the issue. It’s really a question of will. The collective will of a nation to solve a problem. Sure, the recently announced diabetes cure may bear fruit. But, it’s a long way from the lab to marketplace, pointed out Doc. More likely, the answer will come by solving the root cause: obesity. That, says he, will require initiative and the resolve of a nation. Don’t count on that from a country that can’t even agree on restrictions to another public health crisis: the AK-47. We’ve done it before, he points out. As a nation, we’ve proven we can solve big problems in public health. Take water fluoridation, an effort that began in the 1950’s to eradicate tooth decay. By 2020, well over half the U.S. population was getting fluoridation through community water supplies. Eradication of polio, diphtheria, tetanus, pertussis, measles, mumps, and rubella make the point even better: in the U.S., well over 80% of school-age children are vaccinated from the ravages of these and other ailments. The team from Failure—the Podcast/Innovation Blab reminds that parents added fluoride to their toddlers’ morning OJ, before treated water became available.  Perhaps, it’s time to start adding a touch of Ozempic — at least until public works commissions figure out how to get it into community water supplies.   A fat vaccine (aka “faxcine”) offered with the standard series to school children might be even better, though that surely won’t come until there’s a collective will to solve the obesity crisis. And, by the time the populace bellies up to that bar, we might as well simply start eating better. That may prove a better cure than even Big Pharma can provide, with or without an adequate reimbursement mechanism.   In the meanwhile, hold the Ozempic, and pass the iodinated salt. We may not agree on much, but until a fringe Supreme Court decides that the 1st, 5th and/or 14th Amendments to the Constitution trump … er, Trump? … the power of states to regulate public health, we can agree to protect our thyroid glands. Enjoy our little detours into the fun of the ER night shift and popular TV shows as we grill Dr. Seth Powsner on the trials and tribulations of improving public health.

    1 h
  4. 29/07/2024

    Drugged Out

    What?  The team from Failure - the Podcast (a/k/a Innovation Blab) has solved the drug problem?  Cured the common cold?  Ended all plagues and epidemics?  Discovered a magic elixir for aging politicians? Sadly,  no, no, no, and no.   We did, however, stumble upon the dark underbelly of Big Pharma.  Making that stuff isn’t easy. We get it. It’s not like snapping together Legos. You have to try millions of compounds. Some you make. Some you find: Martian asteroids, bottom of the ocean, lizard venom, bee wings, eye of newt. If we were to wax political, it’s not unlike finding a Veep who hates cat-loving, childless woman: you gotta look under a lot of rocks. The guest of today’s podcast has 25+ years of experience at that — Big Pharma, not vetting running mates nor torturing political metaphors. Imran Nasrullah specialized in drug licensing and business development. He tell tales that few know or want to believe. One in ten thousand, for example.  Those are the numbers.  9,999 candidate drugs tested and rejected for one that makes it to the next stage-gate. Do you remember Adam Smith, the 18th-century economist and philosopher? Let’s just say that when it comes bringing product to a market that’s largely defined by 3rd-party payers (read: insurance companies), Smith’s “invisible hand” works in odd ways. The most efficacious drugs aren’t necessarily the ones that either the makers want to make or payers want to pay for. Is there a better way? Who knows. The UK and Canada have not fared better with a single-payer health care system. And, it remains to be seen whether China, which just announced a cure for diabetes, will have the economic wherewithal to bring that to market other than, perhaps, for medical tourism. Getting a face lift in Mexico is so last year.    Join Jeff, David and Mark wrestle with Imran Nasrullah’s picture of a dark aspect of the U.S. health care system which, like democracy, seems the worst there could be, except for all others that have been tried.

  5. 13/07/2024

    Who Knew? A Time-Sink in Two Parts.

    Who knew? Who knew that the presidential election would come down to a flat-liner and a felon? The choice is a no-brainer. Who knew that in a country of over 300,000,000, the major political parties couldn’t find better? Maybe nearly 75 years of media obsession has truly taken a toll. Who knew that we’d record two episodes in one week? Our new co-host, Jeff. Such a task master! Who knew that Mark would take a moment from his busy schedule to join us? Very busy, that Mark is. An important person. That’s what he tells us. Who knew that no-one knows that old saw about failed startups and broken down cars? We guess an old saw it isn’t. Who knew that SpaceX expects to ship 1,000,000 people to Mars within twenty years? We guess the plan is to use their bodies to terraform an acre of the red planet. Who knew that China would take advantage of the Ukrainian quagmire to push into the Russian Far East? Best friends. Hah! Who knew? We’re not saying we’re prescient, but we had a pretty good idea. Put that aside and join the Innovation Blab/Failure - the Podcast in a double-header. A two-fer. “Episode 80 - Broken Down Cars” and “Episode 81 - The Singularity is Nigh.” Our special guests are … well … special. Sydney Robinson is CEO and co-founder of Vessl Prosthetics, an Ontario-based startup that is hellbent on improving the lives of below-knee amputees and on proving that not all orthopedic startups end up like broken down cars along the road to success. We think they’ve got a shot at both. If Sydney can survive 45 minutes of our drivel, she should have no problem navigating the tough medical industry market. Milind Sawant is an AI guru, currently with Siemens Healthcare and leading a team of 50 engineers and a $15M budget to drive AI integration into medical systems. It’s no surprise that Milind is a big fan of AI and the promise it brings to healthcare. That shone through despite Jeff’s probing questions, Dave’s skepticism and Mark’s snoring. (OK, we exaggerate: Mark was no noisier catching Zs than a former president at a felony trial).

    45 min
  6. 13/07/2024

    Who Knew? A Time-Sink in Two Parts.

    Who knew? Who knew that the presidential election would come down to a flat-liner and a felon? The choice is a no-brainer. Who knew that in a country of over 300,000,000, the major political parties couldn’t find better? Maybe nearly 75 years of media obsession has truly taken a toll. Who knew that we’d record two episodes in one week? Our new co-host, Jeff. Such a task master! Who knew that Mark would take a moment from his busy schedule to join us? Very busy, that Mark is. An important person. That’s what he tells us. Who knew that no-one knows that old saw about failed startups and broken down cars? We guess an old saw it isn’t. Who knew that SpaceX expects to ship 1,000,000 people to Mars within twenty years? We guess the plan is to use their bodies to terraform an acre of the red planet. Who knew that China would take advantage of the Ukrainian quagmire to push into the Russian Far East? Best friends. Hah! Who knew? We’re not saying we’re prescient, but we had a pretty good idea. Put that aside and join the Innovation Blab/Failure - the Podcast in a double-header. A two-fer. “Episode 80 - Broken Down Cars” and “Episode 81 - The Singularity is Nigh.” Our special guests are … well … special. Sydney Robinson is CEO and co-founder of Vessl Prosthetics, an Ontario-based startup that is hellbent on improving the lives of below-knee amputees and on proving that not all orthopedic startups end up like broken down cars along the road to success. We think they’ve got a shot at both. If Sydney can survive 45 minutes of our drivel, she should have no problem navigating the tough medical industry market. Milind Sawant is an AI guru, currently with Siemens Healthcare and leading a team of 50 engineers and a $15M budget to drive AI integration into medical systems. It’s no surprise that Milind is a big fan of AI and the promise it brings to healthcare. That shone through despite Jeff’s probing questions, Dave’s skepticism and Mark’s snoring. (OK, we exaggerate: Mark was no noisier catching Zs than a former president at a felony trial).

    45 min
4.4
de 5
23 calificaciones

Acerca de

A podcast about innovation and failure, mostly in business. Visit us at https://innovationblab.com.

Para escuchar episodios explícitos, inicia sesión.

Mantente al día con este programa

Inicia sesión o regístrate para seguir programas, guardar episodios y enterarte de las últimas novedades.

Elige un país o región

Africa, Oriente Medio e India

Asia-Pacífico

Europa

Latinoamérica y el Caribe

Estados Unidos y Canadá